Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in very early axial spondyloarthritis
2023-507718-28-00Phase 2Authorised
- Sponsor
- St. Elisabeth Gruppe
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of risankizumab in axial spondyloarthritis (axSpA), sponsored by St. Elisabeth Gruppe. Primary endpoints: Low disease activity at week 32 and Sustained low disease activity after withdrawal. Planned start Aug 2024; status: authorised.
02
Drugs
risankizumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2023-507718-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507718-28-00.